Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes

Soto-Pérez, Maeve; Rodríguez-Capitán, Jorge; Requena-Ibáñez, Juan Antonio; Santos‐Gallego, Carlos G.; Zafar, M. Urooj; Escolar, Ginés; Mancini, Donna; Mitter, Sumeet S.; Lam, David W.; Contreras, Johanna; Fergus, Icilma; Atallah-Lajam, Farah; Abascal, Vivian M.; Lala, Anu; Moreno, Pedro R.; Moss, Noah; Sanz, Javier; Fuster, Valentı́n; Badimón, Juan J.

doi:10.1007/s10557-023-07469-6

Cited by 8 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the SOLOIST-WHF trial and the SCORED trial showed that in patients with T2D and CKD, the rate of hospitalization and urgent care visits for heart failure was reduced when patients were administered SOTA compared with placebo. A new clinical trial, called the Sotagliflozin in Heart Failure with Preserved Ejection Fraction Patients (SOTA-P-CARDIA) [ 84 ], is currently underway to investigate the SOTA-mediated cardiovascular effects and mechanisms of action in patients with heart failure with preserved ejection fraction (HFpEF) but without diabetes.…”

Section: Discussionmentioning

confidence: 99%

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status

Matthews,

Herat,

Schlaich

et al. 2023

IJMS

View full text Add to dashboard Cite

Chronic Kidney Disease (CKD) and Cardiovascular Disease (CVD) are two devastating diseases that may occur in nondiabetics or individuals with diabetes and, when combined, it is referred to as cardiorenal disease. The impact of cardiorenal disease on society, the economy and the healthcare system is enormous. Although there are numerous therapies for cardiorenal disease, one therapy showing a great deal of promise is sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors. The SGLT family member, SGLT2, is often implicated in the pathogenesis of a range of diseases, and the dysregulation of the activity of SGLT2 markedly effects the transport of glucose and sodium across the luminal membrane of renal cells. Inhibitors of SGLT2 were developed based on the antidiabetic action initiated by inhibiting renal glucose reabsorption, thereby increasing glucosuria. Of great medical significance, large-scale clinical trials utilizing a range of SGLT2 inhibitors have demonstrated both metabolic and biochemical benefits via numerous novel mechanisms, such as sympathoinhibition, which will be discussed in this review. In summary, SGLT2 inhibitors clearly exert cardio-renal protection in people with and without diabetes in both preclinical and clinical settings. This exciting class of inhibitors improve hyperglycemia, high blood pressure, hyperlipidemia and diabetic retinopathy via multiple mechanisms, of which many are yet to be elucidated.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status

Matthews,

Herat,

Schlaich

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“… 85 , 86 , 87 , 88 The ability of these drugs to decrease myocardial inflammation and fibrosis, and to improve microvascular function and ventricular hemodynamics could be explained by a preferential modulation of EAT. 89 SGLT2i may also increase diuresis and mitigate the development of cardiac fibrosis via reduction of the activity of sodium-hydrogen exchangers in the kidney and in the heart.…”

Section: Sglt2i Glp-1ra and Eatmentioning

confidence: 99%

Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction

Goldman,

Requena-Ibanez,

Devesa

et al. 2023

JACC: Advances

Self Cite

View full text Add to dashboard Cite

“…Few advancements in the field of cardiometabolic medicine have had as significant an impact as sodiumglucose cotransporter-2 (SGLT-2) inhibitors [3]. SGLT-2 inhibitors (SGLT-2i) also called gliflozins differ in their relative inhibition of SGLT 1 and 2 receptors [4]. SGLT-2 inhibitors which were initially created as medications for lowering blood sugar levels showed significant outcomes such as reduced HF hospitalization and adverse kidney events in cardiovascular outcome trials [3].…”

Section: Introductionmentioning

confidence: 99%

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality

Iyer,

Hussein,

Singareddy

et al. 2023

Cureus

View full text Add to dashboard Cite

After the debut of the results of the effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) and Sotagliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes (SCORED) trials at the American Heart Association’s 2020 Scientific session, sotagliflozin became the first drug and the third sodium glucose co-transporter-2 (SGLT-2) inhibitor to be approved for heart failure (HF) across the spectrum of ejection fraction (EF). In light of this recent major U.S. Food and Drug Administration (FDA) approval of sotagliflozin, we conducted a systematic review to compare the cardiovascular mortality rates between sotagliflozin and dapagliflozin in patients with HF. To find relevant articles, we extensively searched major research literature databases and search engines such as PubMed, MEDLINE, PubMed Central, Google Scholar, Embase, and Cochrane Library. We compared the results of significant trials involving sotagliflozin with the trials studying dapagliflozin to provide comprehensive mortality results of both drugs. The results showed that the timely initiation of sotagliflozin in HF cases significantly reduces cardiovascular mortality, hospitalizations, and urgent HF visits. Comparative trials with dapagliflozin indicate enhanced mortality reduction associated with greater initial symptom burden. The results of these major trials cannot be overlooked due to the large size of the combined trials, the randomized design, and the high standards with which they were conducted. The pathophysiology behind the cardioprotection offered by these agents is complex and multifactorial, but it is believed that due to the diuretic-like function, SGLT-2 inhibitors reduce glycemic-related toxicity, promote ketogenesis, and exert antihypertrophic, antifibrotic, and anti-remodeling properties. The benefits of dapagliflozin on cardiovascular death and worsening HF in patients with mildly reduced or preserved EF appeared especially pronounced in those with a greater degree of symptomatic impairment at baseline. Sotagliflozin led to a rise in the count of days patients were alive and not hospitalized (DAOH), which offers an extra patient-centered measure to assess the impact of the disease burden. The data in our article will help future researchers conduct large-scale trials with sotagliflozin to identify and implement it in the treatment of patients with HF as a mortality-reducing drug and to improve the quality of life for patients with HF.

show abstract

Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes

Cited by 8 publications

References 46 publications

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status

Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction

Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality

Contact Info

Product

Resources

About